Mayne Pharma Group Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:HG6 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
03 Mar 25	Buy€223,127	Morgan Stanley, Investment Banking and Brokerage Investments	Company	51,919	€4.30
03 Mar 25	Sell€334,802	Morgan Stanley, Investment Banking and Brokerage Investments	Company	78,003	€4.29
28 Feb 25	Sell€27,635,699	Viburnum Funds Pty Ltd.	Company	6,428,268	€4.31
24 Feb 25	Buy€342,218	First Sentier Investors (Australia) IM Ltd	Company	103,984	€4.37
14 Jan 25	Buy€5,772	Morgan Stanley, Investment Banking and Brokerage Investments	Company	2,093	€2.76
27 Nov 24	Buy€340,458	The Vanguard Group, Inc.	Company	130,113	€3.00
17 Oct 24	Buy€4,427,330	MLC Investments Limited	Company	1,579,910	€2.80
15 Oct 24	Sell€626,312	IOOF Investment Management Limited	Company	150,414	€4.40
10 Oct 24	Sell€955,624	MLC Investments Limited	Company	347,961	€2.75
30 Aug 24	Buy€228,872	IOOF Investment Management Limited	Company	90,540	€2.53
25 Jun 24	Sell€80,062	OnePath Funds Management Limited	Company	28,667	€2.79
14 Mar 24	Buy€913,928	UBS Asset Management AG	Company	217,138	€4.21
14 Mar 24	Sell€1,308,391	UBS Asset Management AG	Company	311,656	€4.20

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of HG6?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	7,055,766	8.68%
Private Companies	7,227,977	8.9%
Institutions	32,932,257	40.5%
General Public	34,029,827	41.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 57.47% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
6.51%	Bruce Mathieson	5,292,066	€22.2m	0%	no data
6.38%	Bmgbj Myx Pty Ltd	5,183,477	€21.8m	0%	no data
6.32%	UBS Asset Management AG	5,136,670	€21.6m	172%	no data
5.92%	Goldman Sachs Group, Investment Banking and Securities Investments	4,810,445	€20.2m	0%	0.01%
5.22%	Lazard Asset Management LLC	4,240,774	€17.8m	0%	0.02%
5.14%	Morgan Stanley, Investment Banking and Brokerage Investments	4,180,019	€17.6m	0%	no data
5.11%	The Vanguard Group, Inc.	4,148,229	€17.4m	1.27%	no data
4.27%	MLC Investments Limited	3,472,721	€14.6m	173%	5.18%
2.46%	Dimensional Fund Advisors LP	1,995,866	€8.4m	0.26%	no data
2.09%	Credit Suisse Funds AG	1,701,480	€7.1m	0%	0.11%
1.17%	First Sentier Investors (Australia) IM Ltd	950,443	€4.0m	-66.8%	0.01%
0.98%	IVL Group Pty Ltd	800,000	€3.4m	0%	no data
0.66%	IOOF Investment Management Limited	538,532	€2.3m	0%	0.12%
0.64%	Roger Corbett	522,028	€2.2m	0%	no data
0.63%	Y S Chains Pty Ltd	510,000	€2.1m	0%	no data
0.63%	Zhang Yunsong	510,000	€2.1m	0%	no data
0.52%	Kon Tzimokas	420,000	€1.8m	0%	no data
0.51%	Norges Bank Investment Management	413,308	€1.7m	0%	no data
0.47%	Birbal Investments Pty Ltd	380,000	€1.6m	0%	no data
0.44%	Wal Assets Pty Ltd	354,500	€1.5m	0%	no data
0.42%	Blackstone Inc.	341,518	€1.4m	0%	0.01%
0.39%	Blackstone Alternative Asset Management L.P.	314,685	€1.3m	0%	0.32%
0.31%	OnePath Funds Management Limited	248,106	€1.0m	0%	0.78%
0.18%	Charles Schwab Investment Management, Inc.	147,199	€618.2k	-0.96%	no data
0.094%	BlackRock, Inc.	76,447	€321.1k	-2.69%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/10 20:19
End of Day Share Price	2025/03/10 00:00
Earnings	2024/12/31
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mayne Pharma Group Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
William Dunlop	BofA Global Research
Martyn Jacobs	Canaccord Genuity
Elyse Shapiro	Canaccord Genuity